The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
20121039: MorningStar Partners, L.P.; ExxonMobil Corporation
20121017: Apax Europe VII-B, L.P.; Fox Paine Capital Fund II International, L.P.
20120947: BDCM Opportunity Fund II,L.P.; Onex Partners LP
1207002 Informal Interpretation
1207001 Informal Interpretation
20121029: Time Warner Inc.; Alloy Media Co-Investors, L.L.C.
20120952: R.R. Donnelley & Sons Company; EDGAR Online, Inc.
Michaels Stores, Inc.
20120846: Outokumpu Oyj; ThyssenKrupp AG
20120992: IHS Inc.; Warburg Pincus Equity Partners Liquidating Trust
20120990: DaVita Inc.; HealthCare Partners Medical Group
20120953: Forest Laboratories, Inc.; Nabriva Therapeutics AG
20121016: Microsoft Corporation; Yammer, Inc.
Teva Pharmaceutical Industries Ltd., and Cephalon, Inc., In the Matter of
On 10/7/2011, the FTC required Teva Pharmaceutical Industries Ltd. to sell the rights and assets related to a generic cancer pain drug and a generic muscle relaxant, as a condition of its proposed $6.8 billion acquisition of rival drug firm Cephalon, Inc. In addition, the proposed settlement requires Teva to enter into a supply agreement that will allow a competing firm to sell a generic version of Cephalon’s wakefulness drug Provigil in 2012. On 7/3/2012, the FTC issued its final order. The final amended FTC order resolving the charges requires Teva to sell the rights and assets related to a generic cancer pain drug and a generic muscle relaxant to Par Pharmaceuticals, Inc. It also requires Teva to enter into a supply agreement that will allow Par to sell a generic version of Cephalon's wakefulness drug Provigil in 2012.